<abstract xmlns="http://www.w3.org/1999/xhtml">Previous reports on the clinical significance of anti-Csa(Cost-Stirling) have presented conflicting data. We report our findings, over an 8-month period, of a patient whose serum contained anti-Csa and anti-Fya. Nineteen donor units of ABO and Rh-matched, Fya-negative red cells, which were crossmatch incompatible, were transfused with no clinical, serological, or biochemical evidence of a hemolytic transfusion reaction.</abstract>

Previous reports on the clinical significance of anti-Csa(Cost-Stirling) have presented conflicting data. We report our findings, over an 8-month period, of a patient whose serum contained anti-Csa and anti-Fya. Nineteen donor units of ABO and Rh-matched, Fya-negative red cells, which were crossmatch incompatible, were transfused with no clinical, serological, or biochemical evidence of a hemolytic transfusion reaction.

A case report: clinically benign anti-Csa

Immunohematology

{"article-title":{"content":"A case report: clinically benign anti-Cs","sup":"a"}}

Previous reports on the clinical significance of anti-Csa(Cost-Stirling) have presented conflicting data. We report our findings, over an 8-month period, of a...

A case report: clinically benign anti-Cs^a

Published Online: Dec 20, 2020

Page range: 71 - 72

DOI: https://doi.org/10.21307/immunohematology-2019-1044

© 1990 T. Sererat et al., published by Sciendo.